This site is intended for health professionals only

rFVIII offers hope in haemophilia


Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other haemorrhages in young boys with severe haemophilia A, a small study has concluded.

In the study, 65 five boys younger than 30 months of age with severe haemophilia A were randomly assigned to regular infusions of recombinant factor VIII (prophylaxis, n=32) or to an enhanced episodic infusion schedule of at least three doses totalling a minimum of 80IU/kg bodyweight of factor at the time of a joint haemorrhage (n=33). When the boys reached six years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (p=0.006).

The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5–24.4). The mean annual numbers of joint and total haemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (p<0.001 for both comparisons).

High titres of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening haemorrhage. Hospitalisations and infections associated with central-catheter placement did not differ significantly between the two groups.

N Engl J Med 2007;357:535-44,603-5


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine